Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Modalis Therapeutics Corp.
Industry Sector: HealthTechnology
CEO: Haru Morita
Number Of Employees: 14
Enterprise Value: $7,234,755
PE Ratio: -2.91
Exchange/Ticker 1: Tokyo:4883
Exchange/Ticker 2: N/A
Latest Market Cap: $44,012,265
BioCentury | Mar 21, 2025
Editor's Commentary
Solving CNS delivery will open big doors for epigenome editing: a Perspective
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Jun 2, 2023
Product Development
Epigenome editing companies showcase progress at ASGCT
Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates
BioCentury | Aug 18, 2022
Product Development
Rise of the dead Cas to edit the epigenome
Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery
BioCentury | Oct 10, 2020
Product Development
Next-generation CRISPR technologies keep on building
An analysis of the CRISPR technologies adopted by biotechs
BioCentury | Oct 1, 2020
Finance
Data Bytes: cell and gene therapy IPOs make a strong showing in 3Q20
During the third quarter, seven cell and gene therapy companies brought in an aggregate $1.3 billion through IPOs, most of which priced within or above their proposed ranges. T cell therapy developer
BioCentury | Aug 26, 2020
Finance
Partnerships paved the way to a Tokyo IPO for Modalis
How gene modulation play Modalis charted path to IPO in Japan through platform partnerships
Items per page:
1 - 7 of 7